Editorial: Steroid hormone receptors and cell cycle in breast cancer

Autores
Fabris, Victoria Teresa; Spring Laura; Helguero, Luisa Alejandra
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Breast cancer is the most frequently diagnosed cancer in women with a high incidence and mortality worldwide. Nearly 70% of breast carcinomas express steroid hormone receptors and therefore patients can be treated with endocrine therapy. The treatment is principally targeted to block the estrogen receptor (ER) or estrogen synthesis (1). However, increasing evidence also suggests that the progesterone receptor (PR) is a potential target for therapy (2).
Fil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Spring Laura. Harvard Medical School; Estados Unidos. Massachusetts General Hospital; Estados Unidos
Fil: Helguero, Luisa Alejandra. Universidade de Aveiro; Portugal
Materia
BREAST CANCER
HORMONE RECEPTORS
ENDOCRINE RESISTANCE
CELL CYLCE INHIBITORS
CROSSTALK
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/238246
Acceder
id CONICETDig_34417dfe367a015501ff4b31d3678585
oai_identifier_str oai:ri.conicet.gov.ar:11336/238246
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Editorial: Steroid hormone receptors and cell cycle in breast cancerFabris, Victoria TeresaSpring LauraHelguero, Luisa AlejandraBREAST CANCERHORMONE RECEPTORSENDOCRINE RESISTANCECELL CYLCE INHIBITORSCROSSTALKhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Breast cancer is the most frequently diagnosed cancer in women with a high incidence and mortality worldwide. Nearly 70% of breast carcinomas express steroid hormone receptors and therefore patients can be treated with endocrine therapy. The treatment is principally targeted to block the estrogen receptor (ER) or estrogen synthesis (1). However, increasing evidence also suggests that the progesterone receptor (PR) is a potential target for therapy (2).Fil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Spring Laura. Harvard Medical School; Estados Unidos. Massachusetts General Hospital; Estados UnidosFil: Helguero, Luisa Alejandra. Universidade de Aveiro; PortugalFrontiers Media2023-04-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/238246Fabris, Victoria Teresa; Spring Laura; Helguero, Luisa Alejandra; Editorial: Steroid hormone receptors and cell cycle in breast cancer; Frontiers Media; Frontiers in Endocrinology; 14; 1196523; 12-4-2023; 1-31664-2392CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fendo.2023.1196523info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1196523/fullinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:52:50Zoai:ri.conicet.gov.ar:11336/238246instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:52:50.43CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Editorial: Steroid hormone receptors and cell cycle in breast cancer
title Editorial: Steroid hormone receptors and cell cycle in breast cancer
spellingShingle Editorial: Steroid hormone receptors and cell cycle in breast cancer
Fabris, Victoria Teresa
BREAST CANCER
HORMONE RECEPTORS
ENDOCRINE RESISTANCE
CELL CYLCE INHIBITORS
CROSSTALK
title_short Editorial: Steroid hormone receptors and cell cycle in breast cancer
title_full Editorial: Steroid hormone receptors and cell cycle in breast cancer
title_fullStr Editorial: Steroid hormone receptors and cell cycle in breast cancer
title_full_unstemmed Editorial: Steroid hormone receptors and cell cycle in breast cancer
title_sort Editorial: Steroid hormone receptors and cell cycle in breast cancer
dc.creator.none.fl_str_mv Fabris, Victoria Teresa
Spring Laura
Helguero, Luisa Alejandra
author Fabris, Victoria Teresa
author_facet Fabris, Victoria Teresa
Spring Laura
Helguero, Luisa Alejandra
author_role author
author2 Spring Laura
Helguero, Luisa Alejandra
author2_role author
author
dc.subject.none.fl_str_mv BREAST CANCER
HORMONE RECEPTORS
ENDOCRINE RESISTANCE
CELL CYLCE INHIBITORS
CROSSTALK
topic BREAST CANCER
HORMONE RECEPTORS
ENDOCRINE RESISTANCE
CELL CYLCE INHIBITORS
CROSSTALK
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Breast cancer is the most frequently diagnosed cancer in women with a high incidence and mortality worldwide. Nearly 70% of breast carcinomas express steroid hormone receptors and therefore patients can be treated with endocrine therapy. The treatment is principally targeted to block the estrogen receptor (ER) or estrogen synthesis (1). However, increasing evidence also suggests that the progesterone receptor (PR) is a potential target for therapy (2).
Fil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Spring Laura. Harvard Medical School; Estados Unidos. Massachusetts General Hospital; Estados Unidos
Fil: Helguero, Luisa Alejandra. Universidade de Aveiro; Portugal
description Breast cancer is the most frequently diagnosed cancer in women with a high incidence and mortality worldwide. Nearly 70% of breast carcinomas express steroid hormone receptors and therefore patients can be treated with endocrine therapy. The treatment is principally targeted to block the estrogen receptor (ER) or estrogen synthesis (1). However, increasing evidence also suggests that the progesterone receptor (PR) is a potential target for therapy (2).
publishDate 2023
dc.date.none.fl_str_mv 2023-04-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/238246
Fabris, Victoria Teresa; Spring Laura; Helguero, Luisa Alejandra; Editorial: Steroid hormone receptors and cell cycle in breast cancer; Frontiers Media; Frontiers in Endocrinology; 14; 1196523; 12-4-2023; 1-3
1664-2392
CONICET Digital
CONICET
url http://hdl.handle.net/11336/238246
identifier_str_mv Fabris, Victoria Teresa; Spring Laura; Helguero, Luisa Alejandra; Editorial: Steroid hormone receptors and cell cycle in breast cancer; Frontiers Media; Frontiers in Endocrinology; 14; 1196523; 12-4-2023; 1-3
1664-2392
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3389/fendo.2023.1196523
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1196523/full
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269185479016448
score 13.13397

Publicaciones similares